Article: AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
Clinical cancer research : an official journal of the American Association for Cancer Research
2005 Volume 11, Issue 24 Pt 1, Page(s) 8816–8821
Abstract: Purpose: The aim of this study was to develop an immunostimulating gene therapy for the treatment of orthotopic bladder carcinoma by transferring the gene for CD40L into the tumor site. CD40L stimulation of dendritic cells induces interleukin-12 ... ...
| Abstract | Purpose: The aim of this study was to develop an immunostimulating gene therapy for the treatment of orthotopic bladder carcinoma by transferring the gene for CD40L into the tumor site. CD40L stimulation of dendritic cells induces interleukin-12 expression that drives Th1 type of immune responses with activation of cytotoxic T cells. Experimental design: The gene for murine CD40L was transferred into bladders of tumor-bearing mice using an adenoviral vector construct. To facilitate viral uptake, the bladders were pretreated with Clorpactin. Survival of mice as well as transgene expression and immunologic effect, such as resistance to tumor challenge and presence of T regulatory cells, were monitored. Results: On viral vector instillation, CD40L expression could be detected by reverse transcription-PCR. As a sign of transgene function, interleukin-12 (IL-12) expression was significantly increased. AdCD40L gene therapy cured 60% of mice with preestablished tumors. The cured mice were completely resistant to subcutaneous challenge with MB49 tumor cells, whereas the growth of a syngeneic irrelevant tumor was unaltered. Furthermore, the mRNA expression level of the T regulatory cell transcription factor Foxp3 was evaluated both in tumor biopsies and lymph nodes. There were no differences within the tumors of the different treatment groups. However, Foxp3 mRNA levels were down-regulated in the lymph nodes of AdCD40L-treated mice. Correspondingly, T cells from AdCD40L-treated mice were not able to inhibit proliferation of naive T cells as opposed to T cells from control-treated, tumor-bearing mice. Conclusions: AdCD40L gene therapy evokes Th1 cytokine responses and counteracts T regulatory cell development and/or function. |
|---|---|
| MeSH term(s) | Adenoviridae/genetics ; Animals ; CD40 Ligand/genetics ; Carcinoma/immunology ; Carcinoma/therapy ; Disease Models, Animal ; Epithelium/pathology ; Forkhead Transcription Factors/genetics ; Genetic Therapy ; Genetic Vectors/genetics ; Interleukin-12/genetics ; Lymph Nodes/chemistry ; Mice ; RNA, Messenger/analysis ; RNA, Messenger/metabolism ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; Transduction, Genetic ; Urinary Bladder/pathology ; Urinary Bladder Neoplasms/immunology ; Urinary Bladder Neoplasms/therapy |
| Chemical Substances | Forkhead Transcription Factors ; Foxp3 protein, mouse ; RNA, Messenger ; CD40 Ligand (147205-72-9) ; Interleukin-12 (187348-17-0) |
| Language | English |
| Publishing date | 2005-12-15 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 1225457-5 |
| ISSN | 1557-3265 ; 1078-0432 |
| ISSN (online) | 1557-3265 |
| ISSN | 1078-0432 |
| DOI | 10.1158/1078-0432.CCR-05-1817 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4223: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.